Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441973 · ClinicalTrials.gov registry record · Phase 2
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01441973 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 41 participants.
The verdict
NCT01441973, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56\^dim cells (a marker for the health of the body's immune system)
Interventions
- BIOLOGICAL Elotuzumab (BMS-901608; HuLuc63)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-12-28 |
| Est. Completion | 2017-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441973
The ClinicalTrials.gov registry entry for NCT01441973 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elotuzumab (BMS-901608; HuLuc63) is the first listed.
NCT01441973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01441973 about?
NCT01441973 is a clinical study titled "Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma". The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56\^dim cells (a marker for the health of the body's immune system)
What is the current status of trial NCT01441973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2011-12-28. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT01441973?
The interventions under investigation include: Elotuzumab (BMS-901608; HuLuc63) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01441973?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.